Mesoblast (Mesoblast) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Mesoblast ROE % Adjusted to Book Value?

Mesoblast's ROE % for the quarter that ended in Dec. 2023 was 0.00%. Mesoblast's PB Ratio for the quarter that ended in Dec. 2023 was 0.44. Mesoblast's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was 0.00%.

Mesoblast ROE % Adjusted to Book Value Historical Data

The historical data trend for Mesoblast's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast ROE % Adjusted to Book Value Chart

Mesoblast Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-15.21

-5.96

-9.93

-27.77

-12.24

Mesoblast Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-21.28	-14.29	-13.30	-	-

Competitive Comparison of Mesoblast's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Mesoblast's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mesoblast's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Mesoblast's ROE % Adjusted to Book Value falls into.

Mesoblast ROE % Adjusted to Book Value Calculation

Mesoblast's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-16.40%	/	1.34
	=	-12.24%

Mesoblast's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	0.44
	=	0.00%

Mesoblast ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Mesoblast's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast (Mesoblast) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

MEOBF:USA LWB:Germany MSB:Australia

Address

Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.